A manufacturing collaboration between ten23 health and BD will support the commercialization of a wearable injector platform that offers a ready-to-use option for subcutaneous administration of high-dose biologics.

Claims that the use of acetaminophen/paracetamol while pregnant is linked to autism have been effectively disproved through a rigorous review and meta-analysis of current evidence.

The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.

Despite geopolitical uncertainties, regulatory reforms, and fluctuating capital expenditure, the bio/pharma industry is entering 2026 with renewed focus and confidence.

Facing a world of political risk and scientific hurdles, pharma companies are downsizing internal footprints to focus on portfolio management while leaning on CDMOs for specialized execution, explains Owen Murray from Bend Bioscience.

The company is advancing its lead KV7 potassium channel modulator azetukalner through multiple Phase III trials in epilepsy and mood disorders, and planning its transition to commercial-stage growth.

From managing high viscosity to preventing agglomeration, the industry is shifting toward larger-volume, device-compatible solutions that prioritize both drug stability and healthcare efficiency, points out Dr. Robert Lindner from SCHOTT Pharma.

Changes to sustainability reporting requirements are leading to renewed focus on supplier tools and packaging tenders, and driving a greater need for industry to adapt to ESG standards, reveals Morten Munk from FUJIFILM Biotechnologies.

The agreement will allow AbbVie to develop, manufacture, and commercialize RemeGen’s novel PD-1/VEGF bispecific antibody in combination with its ADCs across multiple solid tumors.

To efficiently and accurately target the immune-rich dermal layer, drug delivery devices must overcome user-dependent variables, explains Michele Guasti from Terumo Medical Care Solutions.

According to Christian Classen from Sanner Group, packaging decisions made too late in the development cycle often lead to avoidable failures in scalability and supply continuity.

While the industry waits for AI-designed drugs to prove their mettle in the clinic, a more immediate return on investment is emerging in the development phase, points out Julien Meissonnier, Independent Director at Prolific Machines.

While GLP-1s will still form part of the conversations at the 2026 J.P. Morgan Healthcare Conference, Julien Meissonnier, Independent Director for Prolific Machines, offers insights into other promising modalities that are worth discussing.

In a market where investor confidence is tied to de-risked programs, the proven ability to solve complex manufacturing challenges, and established regulatory strength, the choice of a CDMO partner has never been more critical, remarks Ryan Lake from Lifecore Biomedical.

Insilico Medicine has entered a multi‑year R&D collaboration with Servier to discover and develop novel AI‑designed oncology therapies. The deal will combine Insilico’s Pharma.AI platform with Servier’s global oncology development and commercialization capabilities.

The first oral GLP-1 for weight loss treatment has been launched in the U.S. by Novo Nordisk, with pricing starting at USD 149 per month and availability at over 70,000 pharmacies in the country.

For Jeremie Trochu from Ardena, therapeutic selectivity, regional manufacturing resilience, and operational connectivity will prove to be critical themes for the industry over the coming months.

Ahead of the 2026 J.P. Morgan Healthcare Conference, Julien Meissonnier, Independent Director for Prolific Machines, breaks down the transitional phase of today’s market, highlighting the unsustainability of de-risking strategies in the long term.

For Megha Sinha from Kamet Consulting Group, industry conversations around key topics are shifting, as companies seek to gain the greatest operational benefits from AI and find ways to improve supply chain resilience without causing chaos.

The PRISM project has the potential to offer a fundamental shift to the way that regulatory bodies and industry collaborate and interact, according to Frits Stulp from Implement Consulting Group.